BAYN.SW Bayer AG (SIX) up 6.57% intraday 21 Jan 2026: watch CHF39.77 breakout
BAYN.SW stock led Swiss healthcare gainers today, climbing 6.57% to CHF39.77 on the SIX intraday session of 21 Jan 2026. Volume was light at 4.00 shares versus a 50-day average of 272.00, but the price jump closed above the 50/200-day average of CHF36.83, signalling a short-term technical shift. Traders cited sector strength and renewed appetite ahead of Bayer’s next earnings date. We examine valuation, catalysts, Meyka AI grading, and a concise outlook for BAYN.SW stock activity today.
Intraday move: BAYN.SW stock performance
Bayer AG (BAYN.SW) moved from a previous close of CHF37.32 to CHF39.77, a +2.45 CHF gain and +6.57% intraday. The session high and low matched CHF39.77, reflecting a tight intraday range. Market cap stands near CHF39.26B and shares outstanding are 982.42M. The jump outpaced the Healthcare sector intraday change of +1.03%, marking BAYN.SW as one of the top gainers on SIX.
Drivers behind the gain: BAYN.SW news and catalysts
The intraday spike follows improved market tone in healthcare and renewed buying ahead of Bayer’s earnings calendar, with the next announcement set for 25 Feb 2026. Short-covering is likely given the low traded volume today versus average. Recent data and broker chatter on product pipelines and Crop Science demand may have amplified the move. For market coverage and local quotes see Investing.com Bayer AG page.
Valuation and metrics: BAYN.SW analysis
Bayer’s trailing EPS is 4.74 with a reported PE of 8.43 on today’s price, indicating value relative to peer healthcare averages. Key ratios: price/book 1.29, price/sales 0.85, free cash flow yield 11.70%, and operating cash flow per share 7.27. Profitability is mixed: gross margin 54.95% but negative net margins in recent TTM data. Current ratio is 1.13 and interest coverage is 2.73, which points to manageable near-term obligations but warrants monitoring.
Meyka AI grade and forecast: BAYN.SW rating and model
Meyka AI rates BAYN.SW with a score of 63.62 out of 100 (B, HOLD). This grade factors S&P 500 and sector comparisons, industry metrics, financial growth, key ratios, forecasts, and analyst consensus. Meyka AI’s forecast model projects a yearly target of CHF56.80, a monthly target of CHF48.24, and a quarterly signal at CHF68.01. Versus the current CHF39.77, the model’s 1-year projection implies an upside of +42.86%. Forecasts are model-based projections and not guarantees.
Technical outlook and price target: BAYN.SW price target and trading notes
Short-term technicals look constructive: price is above the 50/200 averages at CHF36.83, suggesting momentum. We set a conservative near-term price target at CHF42.00, a base case at CHF48.00, and a bull case at CHF57.00, tied to improving fundamentals and successful pipeline news. Traders should watch a stop below CHF36.35 (year low) for risk control. Volume confirmation above the 50-day average would validate a stronger breakout.
Risks and opportunities: BAYN.SW investment considerations
Opportunities include cyclic recovery in Crop Science, steady consumer-health cash flow, and potential earnings beat in February. Risks include margin pressure, litigation or regulatory developments, slower pharma launches, and FX moves. Key red flags: negative net income per share trends and high intangibles to assets. Keep position sizes moderate and link thesis to confirmed earnings or catalyst delivery.
Final Thoughts
BAYN.SW stock’s intraday jump to CHF39.77 on 21 Jan 2026 put Bayer back on watchlists as a top gainer on SIX. Valuation metrics, including PE 8.43 and a price/book of 1.29, argue for a value case if fundamentals stabilise. Meyka AI’s model projects a yearly level of CHF56.80, implying +42.86% upside from today’s price, while our practical near-term targets span CHF42.00–CHF57.00 depending on catalyst flow. Volume remains a key confirm; traders should seek higher liquidity to validate a sustained move. Meyka AI, as an AI-powered market analysis platform, flags BAYN.SW as a HOLD (score 63.62) and recommends monitoring the February earnings release. Forecasts and grades are model outputs and not guarantees; perform your own due diligence before acting.
FAQs
Why did BAYN.SW stock rise today?
BAYN.SW stock rose 6.57% intraday on 21 Jan 2026 due to sector strength, short-covering and pre-earnings positioning. Low traded volume suggests moves were trader-driven rather than broad institutional flows.
What is Meyka AI’s rating for BAYN.SW stock?
Meyka AI rates BAYN.SW 63.62/100 (B, HOLD). The grade uses benchmark, sector, financial growth, key metrics and forecasts. Grades are informational and not investment advice.
What price targets apply to BAYN.SW stock?
We outline a conservative target CHF42.00, base CHF48.00, and bull CHF57.00. Meyka AI’s 1-year model projects CHF56.80, implying roughly +42.86% upside from CHF39.77.
What are the main risks for BAYN.SW stock?
Key risks for BAYN.SW stock include margin pressure, regulatory or litigation outcomes, slower product launches, and currency headwinds. Interest coverage (2.73) and liquidity trends deserve watchful attention.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
